by Raynovich Rod | Jan 27, 2014 | Biopharmaceuticals
Follow Technical Levels -Avoid High Flyers Five Trends To Watch In Biotech-Preliminary Model Large Cap Biopharmaceuticals: metrics already reviewed-awaiting 2013 financial reporting. Key Technicals on Market indices: IBB,XBI,PBE, FBIOX, QQQ. Mid-Cap Emerging Growth in...
by Raynovich Rod | Jan 23, 2014 | Biopharmaceuticals
Update 1/24 With 2 hrs Trading to go…..Technical levels holding with sector up 7-8% YTD. NASDAQ still falling down 1.9% at 4139, QQQ down 1.5% Given the huge 11% move through the J.P.Morgan Conference in January we should only look at technical levels until...
by Raynovich Rod | Jan 23, 2014 | Biopharmaceuticals
Two Large Cap Pharmas Are Now Biotech Stocks: Abbvie, Inc. (ABBV) and Bristol -Myers Squibb (BMY) On our last post on the subject we postulated a model that the bull market in biotechnology would ride with the large cap leaders because they are perceived as growth...
by Raynovich Rod | Jan 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market Enters The Bubblet Phase in Early 2014 (Published in Seeking Alpha on January 9) Buyers Anticipating J.P. Morgan Conference: IBB up 3.79% YTD Last week we started a series of articles that will follow key technical and fundamental trends in the...
by Raynovich Rod | Jan 6, 2014 | Biopharmaceuticals
Celgene (CELG $162) is not on the Rayno biopharmaceutical focus list but it is a good candidate for hedging with a short position or profit taking. Goldman downgraded the stock today from Neutral to SELL . Also, the Wall Street Journal has an article in the...
by Raynovich Rod | Dec 30, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
New Products for Molecular and Companion Diagnostics Drive Growth Rayno Life Science Big Winners-ALR, CSII, ILMN,TMO A diversified life science portfolio must include clinical diagnostics and tools stocks because of the synergies between therapy and diagnostics....
by Raynovich Rod | Dec 24, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Rayno Life Science Stock Picks Beat The Market Everybody now knows about the bull market in biotech stocks. Innovative products, favorable clinical news, M&A (see below) and breakthrough genomic technologies and targeted therapies have driven most life science...
by Raynovich Rod | Dec 19, 2013 | 2024-25 Life Science Portfolios, Macro
Taper Lite With Zero Interest Rates The big FED Meeting with the Bernanke farewell concluded with “taper lite”, optimism on the economy and continued low inflation. The FED decision to roll back its economic stimulus was welcomed by investors boosting the...
by Raynovich Rod | Nov 25, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Up until recently the Fidelity Select Biotechnology Fund (FBIOX) has outperformed all ETFs but now the IBB and PBE are leaders over the last 3 months. There have been two recent mini-corrections but over the past two weeks the IBB has soared up almost 15% for the past...
by Raynovich Rod | Nov 22, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Large Cap Biotechs Rocketing Up:BIIB, GILD Despite a flattish Dow and S&P, many life science stocks are surging ahead. There are many movers in the Rayno Biopharmaceutical Portfolio : Biogen Idec BIIB $277) up 10%, Gilead (GILD $74.40) up 3.88% and Regeneron (REGN...
